Phathom Pharmaceuticals, Inc. (PHAT)
| Market Cap | 566.34M -26.4% |
| Revenue (ttm) | 239.66M +110.2% |
| Net Income | -99.07M |
| EPS | -1.27 |
| Shares Out | 79.43M |
| PE Ratio | n/a |
| Forward PE | 15.80 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 19,277 |
| Open | 7.13 |
| Previous Close | 7.13 |
| Day's Range | 7.13 - 7.20 |
| 52-Week Range | 6.52 - 18.31 |
| Beta | 0.50 |
| Analysts | Buy |
| Price Target | 20.45 (+186.82%) |
| Est. Earnings | Oct 29, 2026 |
About PHAT
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-eros... [Read more]
Financial Performance
In 2025, Phathom Pharmaceuticals's revenue was $175.11 million, an increase of 216.93% compared to the previous year's $55.25 million. Losses were -$221.25 million, -33.82% less than in 2024.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for PHAT stock is "Buy." The 12-month stock price target is $20.45, which is an increase of 186.82% from the latest price.
News
Phathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting
Three scientific presentations will highlight new analyses of VOQUEZNA® (vonoprazan) in GERD, including real-world patient characteristics, efficacy across BMI subgroups, and cost-effectiveness in Ero...
Phathom Pharmaceuticals announces initiation of Phase 3 study of VOQUEZNA
Phathom Pharmaceuticals (PHAT) announced the initiation of patient screening in pHalcon-NERD-302, a registrational Phase 3 study evaluating an as-needed investigational dosing regimen of VOQUEZNA tabl...
Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD
Initiation of registrational Phase 3 study of VOQUEZNA® (vonoprazan) for as-needed (PRN) use in Non-Erosive Reflux Disease (NERD) builds on previously reported positive Phase 2 data Topline results ex...
PHAT Investors Have Opportunity to Join Phathom Pharmaceuticals, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $PHAT--PHAT Investors Have Opportunity to Join Phathom Pharmaceuticals, Inc. Fraud Investigation with SBS Law.
Phathom Pharmaceuticals Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Voquezna’s strong commercial momentum is driven by high efficacy, expanding coverage, and targeted growth in GI practices. Financial performance is robust, with operating profit achieved ahead of schedule and positive cash flow expected next year. Pipeline expansion into EoE and as-needed GERD therapy, along with future OTC potential, positions the product for continued growth.
Phathom Pharmaceuticals Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
A new therapy for gastroesophageal reflux is driving rapid revenue growth and profitability, with peak sales potential exceeding $2B across specialist and primary care channels. Physician adoption is strong, aided by streamlined access, and future growth is supported by pipeline expansion, long exclusivity, and plans for OTC transition.
Leerink starts Phathom Pharmaceuticals at Market Perform on limited upside
As previously reported, Leerink initiated coverage of Phathom Pharmaceuticals (PHAT) with a Market Perform rating and $10 price target Voquenza competes in the “highly genericized” gastroesophageal re...
Phathom Pharmaceuticals initiated with a Market Perform at Leerink
Leerink initiated coverage of Phathom Pharmaceuticals (PHAT) with a Market Perform rating and $10 price target
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
FLORHAM PARK, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastroin...
Phathom Pharmaceuticals price target lowered to $14 from $18 at Barclays
Barclays lowered the firm’s price target on Phathom Pharmaceuticals (PHAT) to $14 from $18 and keeps an Overweight rating on the shares.
Phathom Pharmaceuticals price target lowered to $20 from $22 at Craig-Hallum
Craig-Hallum analyst Chase Knickerbocker lowered the firm’s price target on Phathom Pharmaceuticals (PHAT) to $20 from $22 and keeps a Buy rating on the shares following Q2 earnings. Revenue of…
Phathom Pharmaceuticals price target lowered to $21 from $28 at Raymond James
Raymond James analyst Martin Auster lowered the firm’s price target on Phathom Pharmaceuticals (PHAT) to $21 from $28 and keeps a Strong Buy rating on the shares. The price target…
Phathom Pharmaceuticals price target lowered to $22 from $25 at Guggenheim
Guggenheim lowered the firm’s price target on Phathom Pharmaceuticals (PHAT) to $22 from $25 and keeps a Buy rating on the shares after having updated the firm’s model to reflect…
Phathom Pharmaceuticals price target lowered to $22 from $28 at Needham
Needham lowered the firm’s price target on Phathom Pharmaceuticals (PHAT) to $22 from $28 and keeps a Buy rating on the shares. The company reported Q2 revenue roughly in line…
Phathom Pharmaceuticals Earnings Call Transcript: Q2 2026
Q2 2026 saw 88% year-over-year revenue growth and the first positive operating profit (excl. stock comp), driven by strong VOQUEZNA prescription growth and disciplined expense management. Updated 2026 revenue guidance is $310M-$325M, with continued focus on reducing prescription friction and expanding indications.
Phathom Pharmaceuticals Earnings release: Q2 2026
Phathom Pharmaceuticals released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Phathom Pharmaceuticals Quarterly report: Q2 2026
Phathom Pharmaceuticals has published its Q2 2026 quarterly earnings report on July 30, 2026.
Phathom Pharmaceuticals Slides: Q2 2026
Phathom Pharmaceuticals has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.
Phathom Pharmaceuticals reports Q2 non-GAAP EPS 0c, consensus (9c)
Reports Q2 revenue $74.3M, consensus $72.69M. “Q2 marked an important milestone for Phathom as we delivered strong quarterly revenue growth, achieved operating profitability, excluding stock-based com...
Phathom Pharmaceuticals lowers FY26 revenue view to $310M-$325M from $320M-$345M
FY26 revenue consensus $333.82M.
Phathom Pharmaceuticals Slides: Corporate presentation
Phathom Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on July 30, 2026.
Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
FLORHAM PARK, N.J., July 30, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastroint...
Phathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update on Thursday, July 30, 2026
Management to host conference call on Thursday, July 30, 2026, at 8:00 am EDT Management to host conference call on Thursday, July 30, 2026, at 8:00 am EDT
Phathom Pharmaceuticals completes enrollment in pHalcon-EoE-201 clinical trial
Phathom Pharmaceuticals (PHAT) announced it has completed enrollment in its Phase 2 pHalcon-EoE-201 clinical trial evaluating Voquezna tablets as an investigational treatment for eosinophilic esophagi...
Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
This trial is the first large, placebo-controlled clinical trial of an acid suppression treatment in EoE Topline results for the double-blind 12-week treatment portion of the study are expected in Q4 ...